FAQ

18F-FPPRGD2

Known as: 18F-FP-PEG3-RGD2, [18F] FPPRGD2, 18F-FP-PRGD2 
A radiopharmaceutical agent comprised of a pegylated dimeric arginine-glycine-aspartic acid (RGD)-based peptide labeled with 2-fluoropropionyl, with… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2015
01220092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin
Our previous studies revealed molecular alterations of tumor vessels, varying from immature to mature alterations, resulting from… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements
The aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
2015
2015
Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer
We report the effect of antiangiogenic therapy on the biodistribution of 18F-FPPRGD2 (a surrogate biomarker of integrin αvβ3… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 3
Is this relevant?
2012
2012
Quantitative Analysis and Parametric Imaging of 18F-Labeled Monomeric and Dimeric RGD Peptides Using Compartment Model
Non-invasive PET imaging with radiolabeled RGD peptides for αvβ3 integrin targeting has become an important tool for tumor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
UNLABELLED Abraxane (nanoparticle albumin-bound paclitaxel) is an anticancer drug approved by the Food and Drug Administration… (More)
Is this relevant?
2011
2011
PET imaging of early response to the tyrosine kinase inhibitor ZD4190
We evaluated noninvasive positron emission tomography (PET) imaging for monitoring tumor response to the VEGFR-2 tyrosine kinase… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of αvβ3 Integrin Expression
In vivo imaging of αvβ3 has important diagnostic and therapeutic applications. 18F-Galacto-arginine–glycine–aspartic acid (RGD… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?